7 minute read
Apr. 26, 2023

The First Approved CGRP Receptor Antagonist Nasal Spray for the Treatment of Migraine


CGRP receptor antagonist, first nasal spray FDA-approved for acute migraines in adults rational design based on known CGRP antagonists FDA approval, March 10, 2023 Bristol Myers Squibb, NY / Pfizer, Inc., NY

Drug Hunter Team

Pfizer has announced the FDA-approval of zavegepant ( ZAVZPRET TM , BHV-3500) for the treatment of acute migraine in adults based on positive Ph. II/III results. As the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray [...]



Other molecules you may be interested in